Osteopen 100 mg/ml Solution for Injection for Dogs

A clinical effect may not be observed until after the second injection of the course of
treatment.

Special precautions for safe use in the target species:
Do not exceed the standard dose. Increasing the recommended dose may result in
exacerbation of stiffness and discomfort.
Because of the fibrinolytic action of pentosan polysulphate sodium, the possibility of
internal bleeding from a tumour or vascular abnormality should be considered and
appropriate therapeutic action taken.
It has been reported that a dog which had suffered pulmonary lacerations twelve months
previously had severe pulmonary bleeding after an injection of pentosan polysulphate
sodium. Use with caution in dogs with a history of pulmonary lacerations.
Caution is also recommended in cases of hepatic impairment.
Pentosan polysulphate sodium has an anticoagulant effect.
It is recommended that the Packed Cell Volume (PVC) and capillary filling time should
be monitored, when the veterinary medicinal product is used.
Avoid intramuscular injection because of the risk of haematoma at the injection site.
No more than three courses of four injections should be administered in a twelve month
period.
It is recommended that the animal should be monitored for signs of blood loss and
treated appropriately. Interrupt the treatment if signs of increased bleeding occur.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
The preservative, benzyl alcohol, can cause hypersensitivity (allergic) reactions in
sensitised people. If you know that you are sensitised, care should be taken when
handling this veterinary medicinal product. If accidental skin or eye contact occurs, rinse
affected area immediately with water.
Wash hands after use.
AN: 02382/2024 & 02387/2024
Page 3 of 7Special precautions for the protection of the environment:
Not applicable.